Ligand buys Ryjunea royalty, milestone interest from Sydnexis for $23 million

Bitget2026/09/22 11:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ligand Pharmaceuticals bought a 100% interest in Sydnexis payment rights tied to Santen’s Ryjunea for a USD 23 million upfront payment.
Deal delivers an ascending tiered royalty on Ryjunea net sales in EMEA, ranging from low-double-digits to high-teens.
Transaction also includes certain milestone payments under the existing Sydnexis-Santen license agreement.
Ryjunea is a once-nightly low-dose atropine eye drop to slow pediatric myopia progression, approved in the EU in June 2025.
Sydnexis keeps commercial rights outside Santen-licensed territories, including the U.S.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ligand Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220700PRIMZONEFULLFEED9830979) on September 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ligand buys Ryjunea royalty, milestone interest from Sydnexis for $23 million

You may also like

Crypto prices